Arecor Therapeutics PLC (LSE:AREC) — Market Cap & Net Worth
Market Cap & Net Worth: Arecor Therapeutics PLC (AREC)
Arecor Therapeutics PLC (LSE:AREC) has a market capitalization of $287.12K (GBX2.36 Billion) as of June 20, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31017 globally and #984 in its home market, demonstrating a -9.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arecor Therapeutics PLC's stock price GBX62.50 by its total outstanding shares 37756601 (37.76 Million). Review Arecor Therapeutics PLC total liabilities to assess the company's total debt and financial obligations.
Arecor Therapeutics PLC Market Cap History: 2021 to 2026
Arecor Therapeutics PLC's market capitalization history from 2021 to 2026. Data shows change from $1.84 Million to $287.12K (-23.54% CAGR).
Index Memberships
Arecor Therapeutics PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$939.61 Million | 0.03% | #268 of 722 |
Weight: Arecor Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arecor Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arecor Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Arecor Therapeutics PLC's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.56x
Arecor Therapeutics PLC's market cap is 0.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.84 Million | $1.16 Million | -$6.17 Million | 1.59x | N/A |
| 2022 | $1.10 Million | $2.40 Million | -$9.26 Million | 0.46x | N/A |
| 2023 | $838.38K | $4.57 Million | -$8.55 Million | 0.18x | N/A |
| 2024 | $337.65K | $5.05 Million | -$10.24 Million | 0.07x | N/A |
| 2025 | $369.81K | $1.71 Million | $664.00K | 0.22x | 0.56x |
Competitor Companies of AREC by Market Capitalization
Companies near Arecor Therapeutics PLC in the global market cap rankings as of June 20, 2026.
Key companies related to Arecor Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Arecor Therapeutics PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Arecor Therapeutics PLC's market cap moved from $1.84 Million to $ 287.12K, with a yearly change of -23.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX287.12K | -22.36% |
| 2025 | GBX369.81K | +9.52% |
| 2024 | GBX337.65K | -59.73% |
| 2023 | GBX838.38K | -23.96% |
| 2022 | GBX1.10 Million | -40.00% |
| 2021 | GBX1.84 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Arecor Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $287.12K USD |
| MoneyControl | $287.12K USD |
| MarketWatch | $287.12K USD |
| marketcap.company | $287.12K USD |
| Reuters | $287.12K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more